Search Clinical Trials
There are research studies that need you! MetroHealth conducts research studies and clinical trials to find cures and make new discoveries to improve the health and wellness of our community.
If you are interested in taking part in a MetroHealth research study, please review the list below for all active and enrolling clinical trials at MetroHealth OR narrow your search for specific conditions.
Condition of Interest |
---|
Study Using Negative Pressure to Reduce Apnea
Sleep Apnea, Obstructive
Apnea, Sleep
The objective of this study is to determine the safety and effectiveness of the aerSleepĀ® II
device for treatment of moderate to severe Obstructive Sleep Apnea (OSA) over 24 weeks of
home use in spontaneously breathing adult subjects who are intolerant of Continuous Positive... expand
The objective of this study is to determine the safety and effectiveness of the aerSleepĀ® II device for treatment of moderate to severe Obstructive Sleep Apnea (OSA) over 24 weeks of home use in spontaneously breathing adult subjects who are intolerant of Continuous Positive Airway Pressure (CPAP) therapy. Type: Interventional Start Date: Nov 2021 |
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted...
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Invasive Breast Carcinoma
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating
further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer
who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after... expand
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment. Type: Interventional Start Date: Feb 2020 |
Effect of Heroin Use on Immune Activation and Cardiovascular Risk in HIV
HIV Infection
Opioid-use Disorder
Cardiovascular Diseases
Despite the advent of safer HIV therapies, high levels of markers of systemic inflammation
and increased cardiovascular risk threaten the well-being of individuals living with HIV and
present a significant challenge for HIV providers. These risks may be accentuated in
HIV-infected... expand
Despite the advent of safer HIV therapies, high levels of markers of systemic inflammation and increased cardiovascular risk threaten the well-being of individuals living with HIV and present a significant challenge for HIV providers. These risks may be accentuated in HIV-infected individuals who are active intravenous drug users (IVDU); however, this population has been specifically excluded from prior studies assessing immune activation and cardiovascular risk in people living with HIV. In this study, the investigators will specifically target HIV-infected participants who are active IVDU, and co-enroll a control group of HIV-infected participants who never used IV drugs. The investigators will study the specific alterations in immune activation and several mechanisms felt to be potential drivers of immune activation outside of the IVDU population, namely gut integrity alteration, microbial translocation, and oxidized lipids. The investigators will also study the effect of IVDU on markers of arterial inflammation and vascular function. Importantly, the investigators will study the reversibility of immune activation, gut dysfunction, and cardiovascular markers after cessation of IVDU, and to that effect, compare strategies for IVDU cessation-buprenorphine/naloxone versus methadone or vivitrol maintenance treatment. Type: Observational Start Date: Jul 2017 |
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma
Metastatic Cutaneous Melanoma
Stage III Cutaneous Melanoma AJCC v7
Stage IIIA Cutaneous Melanoma AJCC v7
Stage IIIB Cutaneous Melanoma AJCC v7
Stage IIIC Cutaneous Melanoma AJCC v7
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given
together with or without sargramostim and to see how well they work in treating patients with
stage III-IV melanoma that cannot be removed by surgery (unresectable). Immunotherapy with... expand
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma. Type: Interventional Start Date: Sep 2015 |
The Effect of Positional Therapy on Symptoms of Gastroesophageal Reflux Disease: A Prospective Pilot...
Gastro Esophageal Reflux
Gastroesophageal reflux disease related symptoms are reported by 10-20% of the adult
population and of those 50-75% report symptoms during sleep time. The prevalence of nocturnal
GERD (nGERD) is estimated to be about 25% in general population. nGERD causes sleep
fragmentation,... expand
Gastroesophageal reflux disease related symptoms are reported by 10-20% of the adult population and of those 50-75% report symptoms during sleep time. The prevalence of nocturnal GERD (nGERD) is estimated to be about 25% in general population. nGERD causes sleep fragmentation, difficulty falling asleep, daytime sleepiness, reduced work productivity and decreased quality of life. Additionally, nighttime gastroesophageal reflux has been associated with increased risk of GERD-related complications such as severe erosive esophagitis, peptic stricture, esophageal ulcer, Barrett's esophagus, and esophageal adenocarcinoma. Furthermore, nocturnal gastroesophageal reflux has been noted to be associated with atypical and extra-esophageal manifestations as well as sleep disturbances. Overall, patients with nocturnal gastroesophageal reflux are more likely to develop a more severe form of GERD. The mainstay of treatment of nighttime gastroesophageal reflux is a proton pump inhibitor (PPI). However, nighttime heartburn is the most common breakthrough symptom in patients with GERD, who failed PPI treatment. Other important therapies for nighttime GERD include, lifestyle modifications, such as elevating the head of the bed, avoiding eating at least three hours before bedtime, maintaining appropriate sleep hygiene and avoiding the right decubitus position. Elevating the upper torso by raising the head of the bed and avoiding the right-lateral decubitus position have been shown to improve nocturnal symptoms. Several studies have shown that sleeping in the left decubitus position decrease esophageal acid exposure by reducing 13-76% of the reflux episodes. Studies have shown that the right decubitus position increases the rate of transient lower esophageal sphincter relaxations (TLESRs) accompanied by acid reflux, as compared with the left recumbent position. Moreover, maintaining the left lateral recumbent position, reduced by 87% esophageal acid exposure and nocturnal symptoms. LEFT is a novel electronic wearable device that was developed as a sleep position therapy for patients who suffer from nighttime gastroesophageal reflux symptoms. It is simple, noninvasive and low-cost technology which has been developed by Side Sleep Technologies B.V. Singel, Amesterdam, The Netherland. This technology is designed to train patients to sleep on their left side by a gentle vibration signal once it detects that they are sleeping on their back or right side. Thus, this technique may reduce gastroesophageal reflux and thus provides relief of heartburn and regurgitation during sleep time. The purpose of this study is to determine the usefulness of positional therapy, using the LEFT device, as a nonmedical tool to control GERD-related nocturnal symptoms. Type: Interventional Start Date: Mar 2021 |
Sepsis CDS Master Enrollment Study Protocol
Severe Sepsis
Severe Sepsis Without Septic Shock
This protocol will collect real-world data retrospectively from the electronic health record
[EHR] as data obtained from the delivery of routine medical care to develop a machine
learning [ML]-based Clinical Decision Support [CDS] system for severe sepsis prediction and
detection.... expand
This protocol will collect real-world data retrospectively from the electronic health record [EHR] as data obtained from the delivery of routine medical care to develop a machine learning [ML]-based Clinical Decision Support [CDS] system for severe sepsis prediction and detection. Type: Observational Start Date: Feb 2021 |
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Intracerebral Hemorrhage
Atrial Fibrillation
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite
outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with
recent ICH and atrial fibrillation (AF).
Secondary Aim: To determine if apixaban, compared... expand
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale. Type: Interventional Start Date: Jan 2020 |
Low Voltage-Directed Catheter Ablation for Atrial Fibrillation
Atrial Fibrillation - Symptomatic
A two-pronged approach to evaluate long term success of non-paroxysmal ablation when using a:
1. specified low voltage-directed with pulmonary vein isolation (LD+PVI) approach compared
to ,
2. an approach of pulmonary vein isolation (PVI) alone.
expand
A two-pronged approach to evaluate long term success of non-paroxysmal ablation when using a: 1. specified low voltage-directed with pulmonary vein isolation (LD+PVI) approach compared to , 2. an approach of pulmonary vein isolation (PVI) alone. Type: Interventional Start Date: Feb 2019 |
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin)...
Advanced Vaginal Adenocarcinoma
Advanced Vaginal Adenosquamous Carcinoma
Advanced Vaginal Squamous Cell Carcinoma
Cervical Adenocarcinoma
Cervical Adenosquamous Carcinoma
This randomized phase III trial studies radiation therapy and cisplatin with triapine to see
how well they work compared to the standard radiation therapy and cisplatin alone in treating
patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA... expand
This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy and cisplatin are more effective with triapine in treating cervical or vaginal cancer. Type: Interventional Start Date: Jan 2016 |
Trial to Shorten Pharmacologic Treatment of Newborns With Neonatal Opioid Withdrawal Syndrome (NOWS)
Neonatal Opioid Withdrawal Syndrome
The objective of this study is to evaluate the efficacy of a rapid wean intervention compared
with a slow-wean intervention in reducing the number of days of opioid treatment from the
first dose of weaning to cessation of opioid among infants receiving an opioid (defined as... expand
The objective of this study is to evaluate the efficacy of a rapid wean intervention compared with a slow-wean intervention in reducing the number of days of opioid treatment from the first dose of weaning to cessation of opioid among infants receiving an opioid (defined as morphine or methadone) as the primary treatment for neonatal opioid withdrawal syndrome (NOWS). Type: Interventional Start Date: Sep 2020 |
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
Covid19
This is a randomized, open label, adaptive platform trial to compare the effectiveness of
antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19
positive inpatients
expand
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients Type: Interventional Start Date: Sep 2020 |
Opioid Prescription After Cesarean Trial
Pregnancy Related
Opioid Use
Pain
Non-inferiority randomized trial of 5,500 women with a cesarean delivery randomized prior to
discharge to either an individualized opioid prescription protocol (IOPP) that includes
shared decision making or to a fixed opioid prescription of 20 tablets of oxycodone 5mg.
expand
Non-inferiority randomized trial of 5,500 women with a cesarean delivery randomized prior to discharge to either an individualized opioid prescription protocol (IOPP) that includes shared decision making or to a fixed opioid prescription of 20 tablets of oxycodone 5mg. Type: Interventional Start Date: Sep 2020 |
Nephrotic Syndrome Study Network
Minimal Change Disease (MCD)
Membranous Nephropathy
Glomerulosclerosis, Focal Segmental
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous
nephropathy (MN), generate an enormous individual and societal financial burden, accounting
for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual
cost... expand
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not surprising that the available therapies are imperfect. The therapies lack a clear biological basis, and as many families have experienced, they are often not beneficial, and in fact may be significantly toxic. Given these observations, it is essential that research be conducted that address these serious obstacles to effectively caring for patients. In response to a request for applications by the National Institutes of Health, Office of Rare Diseases (NIH, ORD) for the creation of Rare Disease Clinical Research Consortia, a number of affiliated universities joined together with The NephCure Foundation the NIDDK, the ORDR, and the University of Michigan in collaboration towards the establishment of a Nephrotic Syndrome (NS) Rare Diseases Clinical Research Consortium. Through this consortium the investigators hope to understand the fundamental biology of these rare diseases and aim to bank long-term observational data and corresponding biological specimens for researchers to access and further enrich. Type: Observational Start Date: Apr 2010 |
Comparing Two Methods to Follow Patients With Pancreatic Cysts
Pancreatic Carcinoma
The purpose of this study is to compare the two approaches for monitoring pancreatic cysts.
The study doctors want to compare more frequent monitoring vs less frequent monitoring in
order to learn which monitoring method leads to better outcome for patients with pancreatic... expand
The purpose of this study is to compare the two approaches for monitoring pancreatic cysts. The study doctors want to compare more frequent monitoring vs less frequent monitoring in order to learn which monitoring method leads to better outcome for patients with pancreatic cysts. Type: Interventional Start Date: Jan 2020 |
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering...
Smoldering Plasma Cell Myeloma
This phase III trial studies how well lenalidomide and dexamethasone works with or without
daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in
chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the
growth of tumor... expand
This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma. Type: Interventional Start Date: Apr 2019 |
Composur: Study to Understand the Performance of Vibegron in Participants With Overactive Bladder (OAB)
Overactive Bladder
This study will evaluate the treatment satisfaction, discontinuation, reasons for
discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron
for the treatment of OAB in the context of real-world clinical practice.
expand
This study will evaluate the treatment satisfaction, discontinuation, reasons for discontinuation, quality of life, healthcare resource utilization, and safety with Vibegron for the treatment of OAB in the context of real-world clinical practice. Type: Observational Start Date: Oct 2021 |
Peripheral Nerve Stimulation(PNS) for Subacromial Impingement Syndrome(SIS)
Shoulder Pain
Shoulder Impingement Syndrome
Shoulder Tendinitis
Shoulder Bursitis
Pain, Shoulder
Shoulder pain accounts for 16% of all musculoskeletal complaints in the healthy adult
population. Subacromial impingement syndrome (SIS) is the most common cause of shoulder pain.
Many patients with chronic pain from subacromial impingement syndrome (SIS) will fail
treatment... expand
Shoulder pain accounts for 16% of all musculoskeletal complaints in the healthy adult population. Subacromial impingement syndrome (SIS) is the most common cause of shoulder pain. Many patients with chronic pain from subacromial impingement syndrome (SIS) will fail treatment efforts and have longstanding pain. This project will evaluate the efficacy of a novel approach to treatment, percutaneous peripheral nerve stimulation, for participants with chronic shoulder pain due to subacromial impingement syndrome (SIS). Type: Interventional Start Date: Mar 2019 |
Rehabilitation Enhanced by Partial Arterial Inflow Restrictions
Closed Femur Fracture
The Rehabilitation Enhanced by Partial Arterial Inflow Restriction (REPAIR) Study will be
conducted in a patient population of individuals recovering from a traumatic diaphyseal
fracture of the femur. Although the intervention can be used for any patient with muscle
weakness... expand
The Rehabilitation Enhanced by Partial Arterial Inflow Restriction (REPAIR) Study will be conducted in a patient population of individuals recovering from a traumatic diaphyseal fracture of the femur. Although the intervention can be used for any patient with muscle weakness following trauma, the persistent thigh weakness that follows a femur fracture provides a perfect model for evaluating the effectiveness of the REPAIR protocol. Type: Interventional Start Date: Apr 2016 |
Pravastatin to Prevent Preeclampsia
Preeclampsia
Obstetric Labor Complications
Hypertension in Pregnancy
This study is a double-blind randomized placebo-controlled trial of 1,550 high-risk women to
assess whether daily treatment with pravastatin administered early in pregnancy reduces the
rate of a composite outcome of preeclampsia, fetal loss and maternal death. Women with a... expand
This study is a double-blind randomized placebo-controlled trial of 1,550 high-risk women to assess whether daily treatment with pravastatin administered early in pregnancy reduces the rate of a composite outcome of preeclampsia, fetal loss and maternal death. Women with a prior history of preeclampsia with preterm delivery less than 34 weeks will be randomized to pravastatin or placebo daily until delivery. Women will have monthly study visits during pregnancy, a follow-up visit at 6 weeks postpartum and children will have follow-up visits at 2 and 5 years of age. Type: Interventional Start Date: Jul 2019 |
Two Bag System for Diabetic Ketoacidosis
Diabetic Ketoacidosis
This is a study investigating the best way to treat diabetic ketoacidosis (DKA) with
intravenous (IV) fluids in the hospital. The purpose of this study is to determine whether
the "two bag" system of administering IV fluids for the treatment of adults with DKA leads to
a shorter... expand
This is a study investigating the best way to treat diabetic ketoacidosis (DKA) with intravenous (IV) fluids in the hospital. The purpose of this study is to determine whether the "two bag" system of administering IV fluids for the treatment of adults with DKA leads to a shorter time requiring intravenous insulin (a shorter time to anion gap closure), when compared to usual care the traditional "one bag" system of IV fluids. Participants will be assigned randomly to either the usual care group or the "two bag" system group. Based on studies performed in the past, the investigators predict that patients treated with the two bag system of IV fluids for DKA will have a significantly shorter time requiring treatment with intravenous insulin when compared to the traditional one bag system. Type: Interventional Start Date: Sep 2018 |
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle...
Liver Lymphoma
Mantle Cell Lymphoma
This phase II trial compares three chemotherapy regimens consisting of bendamustine,
rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating
patients with newly diagnosed mantle cell lymphoma. Drugs used in chemotherapy, such as
bendamustine... expand
This phase II trial compares three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib and studies how well they work in treating patients with newly diagnosed mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. This study is being done to find out if one the drug combinations of bendamustine, rituximab, high dose cytarabine, and acalabrutinib is better or worse than the usual approach for mantle cell lymphoma. Type: Interventional Start Date: Oct 2019 |
Evaluation of an Advanced Lower Extremity Neuroprostheses
Spinal Cord Injuries
Stroke
Paralysis
Tetraplegia
Paraplegia
The purpose of this study is to evaluate a surgically implanted functional electrical
stimulation (FES) system to facilitate exercise, standing, stepping and/or balance in people
with various degrees of paralysis.
expand
The purpose of this study is to evaluate a surgically implanted functional electrical stimulation (FES) system to facilitate exercise, standing, stepping and/or balance in people with various degrees of paralysis. Type: Interventional Start Date: Jun 2018 |
Therapies for Recovery of Hand Function After Stroke
Stroke
Upper Extremity Paresis
Hemiplegia
After a stroke, it is very common to lose the ability to open the affected hand. The purpose
of this study is to compare the effects of three different therapies on recovery of hand
function after stroke and determine if any one is better than the other.
expand
After a stroke, it is very common to lose the ability to open the affected hand. The purpose of this study is to compare the effects of three different therapies on recovery of hand function after stroke and determine if any one is better than the other. Type: Interventional Start Date: Feb 2019 |
Pre-exposure Prophylaxis (PrEP) at Home
HIV/AIDS
This study is a randomized clinical trial of PrEP@Home, a home care system for Human
Immunodeficiency Virus (HIV) Pre-Exposure Prophylaxis (PrEP). Individuals entering into PrEP
care at an initial in-person study visit will be randomized to the PrEP@Home system for
home-based... expand
This study is a randomized clinical trial of PrEP@Home, a home care system for Human Immunodeficiency Virus (HIV) Pre-Exposure Prophylaxis (PrEP). Individuals entering into PrEP care at an initial in-person study visit will be randomized to the PrEP@Home system for home-based PrEP care follow-up visits or to the control standard of care for clinic-based follow-up visits. The primary aim of this study is to assess protective levels of PrEP medication for the intervention arm compared to the control arm. Type: Interventional Start Date: Apr 2019 |
Understanding the Long-term Impact of COVID-19 in Adults
SARS-CoV2 Infection
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of
individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying
stages before and after infection. Individuals with and without SARS-CoV-2 infection and with... expand
This is a combined retrospective and prospective, longitudinal, observational meta-cohort of individuals who will enter the cohort with and without SARS-CoV-2 infection and at varying stages before and after infection. Individuals with and without SARS-CoV-2 infection and with or without Post-Acute Sequelae of COVID-19 (PASC) symptoms will be followed to identify risk factors and occurrence of PASC. This study will be conducted in the United States and subjects will be recruited through inpatient, outpatient, and community-based settings. Study data including age, demographics, social determinants of health, medical history, vaccination history, details of acute SARS-CoV-2 infection, overall health and physical function, and PASC symptom screen will be reported by subjects or collected from the electronic health record using a case report form at specified intervals. Biologic specimens will be collected at specified intervals, with some tests performed in local clinical laboratories and others performed by centralized research centers or banked in the Biospecimen Repository. Advanced clinical examinations and radiologic examinations will be performed at local study sites with cross-site standardization. Type: Observational Start Date: Oct 2021 |
- Previous
- Next